Human steroid biosynthesis for the oncologist

Journal of Investigative Medicine

Volumn 60, Issue 2, 2012, Pages 495-503

  Auchus, Mary Louise ^a,b   Auchus, Richard J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Abiraterone acetate; Aromatase inhibitor; Breast cancer; Prostate cancer; Steroid biosynthesis

Indexed keywords

ABIRATERONE ACETATE; ANASTROZOLE; AROMATASE INHIBITOR; DOCETAXEL; PREDNISONE; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CONFERENCE PAPER; HUMAN; STEROIDOGENESIS;

ANIMALS; BIOSYNTHETIC PATHWAYS; FEEDBACK, PHYSIOLOGICAL; HUMANS; NEOPLASMS; PHYSICIANS; STEROIDS;

EID: 84856700317     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182408567     Document Type: Conference Paper

References (63)

1. Boyd S. On oophorectomy in cancer of the breast. BMJ. 1900;2:1161-1167.
2. Huggins C. Prostatic cancer treated by orchiectomy; the five year results. JAMA. 1946;15:576-581.
3. Huggins C, Dao TL. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA. 1953;18:1388-1394.
4. Santen RJ, Worgul TJ, Samojlik E, et al. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med. 1981;305:545-551. (Pubitemid 12201131)
5. Susan LP, Roth RB, Adkins WC. Regression of prostate cancer metastasis by high doses of diethylsilbestrol phosphate. Urology. 1976;7:598-601.
6. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984;311:1281-1286.
7. Schellhammer PF, Sharifi R, Block NL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormoneYreleasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996;78:2164-2169. (Pubitemid 26367610)
8. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618. (Pubitemid 28536137)
9. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139. (Pubitemid 34694019)
10. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
11. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81-151.
12. Miller WL. Lessons from congenital lipoid adrenal hyperplasia. Curr Opin Endocrinol Diabetes. 1998;5:155-161. (Pubitemid 28311501)
13. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:113-118.
14. Griffin JE. Androgen resistanceVthe clinical and molecular spectrum. N Engl J Med. 1992;326:611-618.
15. Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab. 1998;12:67-81. (Pubitemid 28495390)
16. Clark BJ, Wells J, King SR, et al. The purification, cloning and expression of a novel luteinizing hormoneYinduced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem. 1994;269:28314-28322.
17. Tsujishita Y, Hurley JH. Structure and lipid transport mechanism of a StAR-related domain. Nat Struct Biol. 2000;7:408-414. (Pubitemid 30250006)
18. Bose H, Lingappa VR, Miller WL. Rapid regulation of steroidogenesis by mitochondrial protein import. Nature. 2002;417:87-91. (Pubitemid 34498821)
19. Arakane F, King SR, Du Y, et al. Phosphorylation of steroidogenic acute regulatory protein (StAR) modulates its steroidogenic activity. J Biol Chem. 1997;272:32656-32662. (Pubitemid 28011957)
20. Lin D, Sugawara T, Strauss JF III, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science. 1995;267:1828-1831.
21. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-4454.
22. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503-6513.
23. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010;70:1256-1264.
24. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1-51. (Pubitemid 23064489)
25. Khan N, Sharma KK, Andersson S, et al. Human 17A-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch Biochem Biophys. 2004;429:50-59. (Pubitemid 39022591)
26. Mizrachi D, Auchus RJ. Androgens, estrogens, and hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 2009;301:37-42.
27. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroiditism caused by mutations of testicular 17A-hydroxysteroid dehydrogenase 3. Nat Genet. 1994;7:34-39.
28. Wu L, Einstein M, Geissler WM, et al. Expression cloning and characterization of human 17A-hydrosteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993;268:12964-12969. (Pubitemid 23182471)
29. Simard J, Sanchez R, Durocher F, et al. Structure-function relationships and molecular genetics of the 3A-hydroxysteroid dehydrogenase gene family. J Steroid Biochem Mol Biol. 1995;55:489-505. (Pubitemid 26022382)
30. Labrie F, Luu-The V, Lin SX, et al. Role of 17A-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab. 2000;11:421-427.
31. Turgeon D, Carrier JS, Levesque E, et al. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology. 2001;142:778-787. (Pubitemid 32222427)
32. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854. (Pubitemid 28096082)
33. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1996;81:1460-1464. (Pubitemid 26118577)
34. Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, et al. Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11A-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91:2179-2184. (Pubitemid 43855002)
35. Flück CE, Miller WL, Auchus RJ. The 17, 20-lyase activity of cytochrome P450c17 from human fetal testis favors the $5 steroidogenic pathway. J Clin Endocrinol Metab. 2003;88:3762-3766. (Pubitemid 37034525)
36. Chang KH, Li R, Papari-Zareei M, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011;108:13728-13733.
37. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab. 2004;15:432-438. (Pubitemid 39440726)
38. Wilson JD, Auchus RJ, Leihy MW, et al. 5α-Androstane-3α,17A- diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology. 2003;144:575-580. (Pubitemid 36205230)
39. Wilson JD, Shaw G, Leihy ML, et al. The marsupial model for male phenotypic development. Trends Endocrinol Metab. 2002;13:78-83. (Pubitemid 36740451)
40. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-790.
41. Ryan CJ, Halabi S, Ou SS, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007;13:2030-2037. (Pubitemid 46649869)
42. Patel SR, Kvols LK, Hahn RG, et al. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer. 1990;66:655-658. (Pubitemid 20281305)
43. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:463-4571.
44. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742-3748.
45. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317-2325. (Pubitemid 38961894)
46. Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am. 2001;30:101-119. (Pubitemid 32381716)
47. Costa-Santos M, Kater CE, Auchus RJ. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab. 2004;89:49-60. (Pubitemid 38183859)
48. Biglieri EG, Herron MA, Brust N. 17α-Hydroxylation deficiency in man. J Clin Invest. 1966;15:1945-1954.
49. Attard G, Reid AHM, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. In press.
50. Labrie F. Endocrine therapy of prostate cancer: optimal form and timing. J Clin Endocrinol Metab. 1995;80:1066-1071.
51. Penning TM, Steckelbroeck S, Bauman DR, et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol. 2006;248:182-191.
52. Sharifi N, McPhaul MJ, Auchus RJ. ''Getting from here to there''Vmechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer. J Investig Med.2010;58:938-944.
53. Judd HL, Shamonki IM, Frumar AM, et al. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982;59:680-686. (Pubitemid 12107424)
54. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15:342-355. (Pubitemid 24180792)
55. Santner SJ, Pauley RJ, Tait L, et al. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab. 1997;82:200-208. (Pubitemid 27021297)
56. Rugo HS. The breast cancer continuum in hormone-receptorYpositive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008;19:16-27.
57. Recchia F, Candeloro G, Necozione S, et al. Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy. Anticancer Res. 2011;31:671-676.
58. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444-2447. (Pubitemid 46630620)
59. Ortmann O, Pagani O, Jones A, et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev. 2011;37:97-104.
60. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671-1676.
61. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorYpositive breast cancer: status report 2004. J Clin Oncol. 2005;23:619-629. (Pubitemid 46224240)
62. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003;98:703-711. (Pubitemid 36959265)
63. Sikora MJ, Cordero KE, Larios JM, et al. The androgen metabolite 5α-androstane-3A,17A-diol (3AAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat. 2009;115:289-296.